Weyland, Charlotte S.
Vey, Johannes A.
Mokli, Yahia
Feisst, Manuel
Kieser, Meinhard
Herweh, Christian
Schönenberge, Silvia
Möhlenbruch, Markus A.
Bendszus, Martin
Ringleb, Peter A.
Nagel, Simon http://orcid.org/0000-0003-2471-6647
Funding for this research was provided by:
Ruprecht-Karls-Universität Heidelberg
Article History
Received: 12 January 2022
Accepted: 25 March 2022
First Online: 9 May 2022
Declarations
:
: All authors declare that there is no conflict of interest related to the submitted study and manuscript. Disclosures: C. S. Weyland—none. J. A. Vey—none. Y. Mokli—none. M. Feisst—none. M. Kieser—none. C. Herweh—UNRELATED: Consultancy: Brainomix, Oxford, UK. S. Schönenberger—none. M. Bendszus—UNRELATED: Grants from Siemens, grants and personal fees from Novartis, grants from Stryker, grants from DFG, personal fees from Merck, personal fees from Bayer, personal fees from Teva, grants and personal fees from Guerbet, personalfees from Boehringer, personal fees from Vascular Dynamics, personal fees from Grifols, and grants from European Union, all outside the submitted work. M. A. Möhlenbruch—UNRELATED: Board Membership: Codman; Consultancy: Medtronic, MicroVention, Stryker; Payment for Lectures Including Service on Speakers Bureaus: Medtronic, MicroVention, Stryker. *Money paid to the institution. P. A. Ringleb—UNRELATED: Consultancy: Boehringer, Lecture fees from Bayer, Boehringer Ingelheim, BMS, Daichii Sankyo, Pfizer. S. Nagel—UNRELATED: Consultancy: Brainomix, Boehringer Ingelheim; Payment for Lectures Including Service on Speakers Bureaus: Pfizer, Medtronic, Bayer AG.
: This study was approved by the local ethics committee and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.